Replies to post #4389 on NorthWest Biotherapeutics Inc (NWBO)

[nbinvest]

March 11.2011?

[FatCat_Banker]

Old article

[f3tt3f]

Would be interesting to know if the mesenchymal subtype is one of the P3's monitored subgroups (i.e. "chances to win"). If pre-defined in the trial design, FDA might be more likely to consider it as a potential subset for post hoc analysis approval (if necessary).
If only downloaded that darned pdf.....